Skip to main content
. 2016 Jun 9;115(1):34–39. doi: 10.1038/bjc.2016.155

Table 2. Risk factors for any metastasis and for any hepatic metastasis.

  Any metastasis
Hepatic metastasis
  Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
Validate HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age >75 1.36 0.91–2.04 0.13 1.24 0.85–1.80 0.26 1.21 0.59–2.50 0.60 0.89 0.40–1.96 0.77
Sex 0.92 0.66–1.27 0.60 0.85 0.61–1.17 0.31 0.95 0.50–1.83 0.89 0.88 0.46–1.69 0.70
Body mass index >25 0.57 0.35–0.95 0.03       1.17 0.57–2.40 0.68      
AST >35 1.83 1.07–3.15 0.03       0.33 0.46–2.42 0.28      
ALT >35 1.62 0.97–2.71 0.07       1.79 0.75–4.29 0.19      
Platelet count >100  000 1.79 0.25–12.8 0.56       0.58 0.80–4.24 0.59      
CEA >5.0 ng ml−1 1.90 1.31–2.75 <0.01       1.72 0.89–3.33 0.11      
Diabetes mellitus 1.11 0.74–1.65 0.62       1.78 0.88–3.59 0.11      
Hepatic virus 1.07 0.53–2.19 0.84       1.09 0.26–4.54 0.90      
Hepatic fibrosis 1.76 1.05–2.97 0.03 1.30 0.75–2.25 0.34 2.84 1.25–6.44 0.01 2.87 1.17–7.02 0.02
Location                        
 Right-sided colon Ref       Ref      
 Left-sided colon 0.93 0.64–1.35 0.71       1.05 0.52–2.11 0.89      
 Rectum 1.37 0.92–2.05 0.16       0.73 0.28–1.91 0.52      
Vascular invasion 3.42 2.25–5.22 <0.01 1.86 1.21–2.87 <0.01 4.43 1.72–11.3 <0.01 2.81 1.06–7.43 0.04
Stage                        
 I Ref Ref Ref Ref
 II 7.62 3.02–19.2 <0.01 7 2.75–17.8 <0.01 3.80 1.07–13.5 0.04 2.75 0.76–9.98 0.13
 III 19.4 7.92–47.7 <0.01 17.9 7.21–44.7 <0.01 8.02 2.41–26.7 <0.01 5.44 1.57–18.9 <0.01
PS 0, 1/2, 3 and 4 0.93 0.29–2.98 0.90       0.44 0.06–3.18 0.41      

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; CEA=carcinoembryonic antigen; CI=confidence interval; HR=hazard ratio; PS=performance status; Ref=reference.